Table 2.
Patient characteristics at baseline based on pathological response (Subgroup : Neoadjuvant Chemoradiotherapy).
| Characteristics | Before PSM | After PSM | ||||||
|---|---|---|---|---|---|---|---|---|
| All patients N = 166 |
Patients with major pathological response N = 96 | Patients without major pathological response N = 70 | P-value | All patients N = 118 |
Patients with major pathological response N = 59 | Patients without major pathological response N = 59 | P-value | |
| Age (Mean ± SD) | 61.1 ± 7.1 | 61.2 ± 7.0 | 60.9 ± 7.2 | 0.759 | 60.7 ± 7.3 | 61.1 ± 7.1 | 60.1 ± 7.6 | 0.517 |
| Gender Male Female |
143 (86.1%) 23 (13.9%) |
80 (83.3%) 16 (16.7%) |
63 (90.0%) 7 (10.0%) |
0.220 |
105 (89.0%) 13 (11.0%) |
53 (89.8%) 6 (10.2%) |
52 (88.1%) 7 (11.9%) |
0.769 |
| Smoking history Yes No |
113 (68.1%) 53 (31.9%) |
61 (63.5%) 35 (36.5%) |
46 (65.7%) 24 (34.3%) |
0.773 |
88 (74.6%) 30 (25.4%) |
44 (74.6%) 15 (25.4%) |
44 (74.6%) 15 (25.4%) |
1.000 |
| Drinking history Yes No |
109 (65.7%) 57 (34.3%) |
67 (69.8%) 29 (30.2%) |
48 (68.6%) 22 (31.4%) |
0.886 |
86 (72.9%) 32 (27.1%) |
43 (72.9%) 16 (27.1%) |
43 (72.9%) 16 (27.1%) |
1.000 |
| Clinical Stage (8th edition) I II III IVa |
4 (1.5%) 13 (7.8%) 114 (68.7%) 35 (21.1%) |
3 (3.1%) 9 (9.4%) 65 (67.7%) 19 (19.8%) |
1 (1.4%) 4 (5.7%) 49 (70.0%) 16 (22.9%) |
0.745 |
1 (0.8%) 8 (6.8%) 81 (68.6%) 28 (23.7%) |
0 (0%) 4 (6.8%) 41 (69.5%) 14 (23.7%) |
1 (1.7%) 4 (6.8%) 40 (67.8%) 14 (23.7%) |
1.000 |
| Tumor location Upper Middle Lower |
27 (16.3%) 80 (48.2%) 59 (35.5%) |
19 (19.8%) 51 (53.1%) 26 (27.1%) |
8 (11.4%) 29 (41.4%) 33 (47.1%) |
0.023* |
14 (11.9%) 60 (50.8%) 44 (37.3%) |
6 (10.2%) 33 (55.9%) 20 (33.9%) |
8 (13.6%) 27 (45.8%) 24 (40.7%) |
0.535 |
* P-value < 0.05.
PSM, propensity score matching.